What's Happening?
Pfizer is making a significant entry into the in vivo CAR T therapy space for autoimmune diseases through a deal with China's Starna Therapeutics, potentially valued at up to $2.6 billion. The agreement includes an upfront payment of $330 million and
up to $2.3 billion in milestone payments, plus royalties. This collaboration will focus on developing three preclinical CAR T therapies for autoimmune conditions. While Pfizer has previously explored ex vivo CAR T in oncology, this marks its first venture into in vivo CAR T, which involves generating CAR T cells inside the body. The deal aims to strengthen Pfizer's immunology and inflammation (I&I) pipeline and grants Pfizer rights to Starna's in vivo CAR T technology for both I&I and oncology indications. Starna specializes in RNA medicines delivered via a targeted lipid nanoparticle (LNP) platform, an area where Pfizer also possesses significant scientific expertise.
Why It's Important?
This strategic move by Pfizer is important for the U.S. pharmaceutical industry as it signifies a major investment in a cutting-edge therapeutic area, particularly for autoimmune diseases, where there is a high unmet medical need. The entry into in vivo CAR T therapy could revolutionize treatment options for patients, offering a potentially less invasive and more accessible approach compared to traditional ex vivo CAR T therapies. The substantial financial commitment underscores Pfizer's confidence in this technology and its potential to generate significant revenue. The collaboration with a Chinese biotech firm, Starna Therapeutics, also highlights the increasing global nature of pharmaceutical innovation and the willingness of U.S. companies to partner internationally to access advanced technologies. This deal could set a precedent for future cross-border collaborations in the rapidly evolving field of cell therapy, impacting research and development strategies across the industry.
What's Next?
The immediate next steps involve the preclinical development of the three CAR T therapies for autoimmune diseases. Pfizer and Starna Therapeutics will work to advance these candidates through the early stages of research, with the goal of moving them into clinical trials. The success of these therapies could lead to further expansion of Pfizer's CAR T pipeline and potentially new treatment paradigms for autoimmune conditions. The deal also includes a separate research collaboration that could yield additional compounds, indicating a long-term partnership. The industry will be closely watching the safety and efficacy data from these programs, especially given recent safety concerns surrounding CAR T therapies from other companies like Novartis and Bristol Myers Squibb. This collaboration could also spur other major pharmaceutical companies to increase their investments in in vivo CAR T technology, intensifying competition and accelerating innovation in the field.
Beyond the Headlines
Pfizer's venture into in vivo CAR T therapy with Starna Therapeutics represents a significant technological leap, moving towards a future where complex cell therapies might be administered more simply and broadly. This could democratize access to advanced treatments, potentially reducing the logistical and financial burdens associated with current ex vivo CAR T approaches. However, the deal also raises questions about the increasing reliance of U.S. pharmaceutical giants on foreign, particularly Chinese, innovation for critical therapeutic advancements. While beneficial for accessing cutting-edge science, it could also contribute to concerns about the U.S.'s long-term leadership in biopharmaceutical innovation and national security implications related to drug supply chains. The success of this partnership could influence future regulatory pathways for in vivo gene and cell therapies, potentially streamlining approval processes for these novel treatments.













